Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Russell 2000 ETF (IWM) vs Moderna, Inc. (MRNA) Price & Performance

iShares Russell 2000 ETFTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

iShares Russell 2000 ETF vs Moderna, Inc. — how do they compare? iShares Russell 2000 ETF trades at $302.42, while Moderna, Inc. trades at $63.63 (market cap $24.18B). The key difference: iShares Russell 2000 ETF is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.

IWMMRNA
52-Week High
$301.69$81.80
52-Week Low
$225.45$22.36
Market Cap
$24.18B
Sector
Health
Enterprise Value
$20.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Russell 2000 ETF

IWM trades at $302.3, up 0.77% with a bullish technical outlook supported by moving averages, though RSI suggests mild overbought conditions. The ETF, tracking the Russell 2000 small-cap index, benefits from institutional favor due to deep liquidity and options markets. Small caps are outperforming large caps year-to-date, with the Russell 2000 up approximately 20% as of July 17, 2026 (24/7 Wall Street).

Outlook remains positive for small-cap exposure amid broadening market rally, but risks include higher volatility and economic sensitivity. Investors gain diversified small-cap access, yet should monitor valuation gaps versus alternatives and interest rate impacts highlighted by Goldman Sachs on July 7, 2026.

Moderna, Inc.

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Russell 2000 ETF

The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on IWM

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA